Literature DB >> 20716773

Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin.

Leah N Cueni1, Lu Chen, Hui Zhang, Daniela Marino, Reto Huggenberger, Annamari Alitalo, Roberta Bianchi, Michael Detmar.   

Abstract

Podoplanin is a small transmembrane protein required for development and function of the lymphatic vascular system. To investigate the effects of interfering with its function, we produced an Fc fusion protein of its ectodomain. We found that podoplanin-Fc inhibited several functions of cultured lymphatic endothelial cells and also specifically suppressed lymphatic vessel growth, but not blood vessel growth, in mouse embryoid bodies in vitro and in mouse corneas in vivo. Using a keratin 14 expression cassette, we created transgenic mice that overexpressed podoplanin-Fc in the skin. No obvious outward phenotype was identified in these mice, but surprisingly, podoplanin-Fc-although produced specifically in the skin-entered the blood circulation and induced disseminated intravascular coagulation, characterized by microthrombi in most organs and by thrombocytopenia, occasionally leading to fatal hemorrhage. These findings reveal an important role of podoplanin in lymphatic vessel formation and indicate the potential of podoplanin-Fc as an inhibitor of lymphangiogenesis. These results also demonstrate the ability of podoplanin to induce platelet aggregation in vivo, which likely represents a major function of lymphatic endothelium. Finally, keratin 14 podoplanin-Fc mice represent a novel genetic animal model of disseminated intravascular coagulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716773      PMCID: PMC2993634          DOI: 10.1182/blood-2010-04-278564

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

Review 1.  The lymphatic system in health and disease.

Authors:  Leah N Cueni; Michael Detmar
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

2.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

3.  Growth hormone promotes lymphangiogenesis.

Authors:  Nadja Erika Banziger-Tobler; Cornelia Halin; Kentaro Kajiya; Michael Detmar
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

4.  Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions.

Authors:  Leah N Cueni; Michael Detmar
Journal:  Exp Cell Res       Date:  2009-03-04       Impact factor: 3.905

5.  Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.

Authors:  Jay W Shin; Reto Huggenberger; Michael Detmar
Journal:  Blood       Date:  2008-07-09       Impact factor: 22.113

6.  Very late antigen 1 blockade markedly promotes survival of corneal allografts.

Authors:  Lu Chen; Syed Huq; Humphrey Gardner; Antonin R de Fougerolles; Stefano Barabino; M Reza Dana
Journal:  Arch Ophthalmol       Date:  2007-06

7.  Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice.

Authors:  Jianxin Fu; Holger Gerhardt; J Michael McDaniel; Baoyun Xia; Xiaowei Liu; Lacramioara Ivanciu; Annelii Ny; Karlien Hermans; Robert Silasi-Mansat; Samuel McGee; Emma Nye; Tongzhong Ju; Maria I Ramirez; Peter Carmeliet; Richard D Cummings; Florea Lupu; Lijun Xia
Journal:  J Clin Invest       Date:  2008-10-16       Impact factor: 14.808

8.  Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.

Authors:  Katsue Suzuki-Inoue; Yukinari Kato; Osamu Inoue; Mika Kato Kaneko; Kazuhiko Mishima; Yutaka Yatomi; Yasuo Yamazaki; Hisashi Narimatsu; Yukio Ozaki
Journal:  J Biol Chem       Date:  2007-07-06       Impact factor: 5.157

9.  Soluble Flt-1 regulates Flk-1 activation to control hematopoietic and endothelial development in an oxygen-responsive manner.

Authors:  Kelly A Purpura; Sophia H L George; Stephen M Dang; Kyunghee Choi; Andras Nagy; Peter W Zandstra
Journal:  Stem Cells       Date:  2008-09-04       Impact factor: 6.277

10.  Fusion protein consisting of the first immunoglobulin-like domain of porcine nectin-1 and Fc portion of human IgG1 provides a marked resistance against pseudorabies virus infection to transgenic mice.

Authors:  Yukiko Tomioka; Masami Morimatsu; Keiko Amagai; Minako Kuramochi; Yuki Watanabe; Shigeto Kouda; Toshio Wada; Noritaka Kuboki; Etsuro Ono
Journal:  Microbiol Immunol       Date:  2009-01       Impact factor: 1.955

View more
  25 in total

1.  Investigation of biomarker in laryngeal carcinomas.

Authors:  Deniz Kanliada; Ender Coskunpinar; Kadir Serkan Orhan; Yasemin Musteri Oltulu; Mehmet Celik; Ayse Eren; Ilhan Yaylim; Kemal Deger
Journal:  J Clin Lab Anal       Date:  2014-01-06       Impact factor: 2.352

2.  Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.

Authors:  Roberta Bianchi; Eliane Fischer; Don Yuen; Ellen Ernst; Alexandra M Ochsenbein; Lu Chen; Vivianne I Otto; Michael Detmar
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

Review 3.  Podoplanin--a novel marker in oral carcinogenesis.

Authors:  Niharika Swain; Shwetha V Kumar; Samapika Routray; Jigna Pathak; Shilpa Patel
Journal:  Tumour Biol       Date:  2014-06-27

Review 4.  Podoplanin - a small glycoprotein with many faces.

Authors:  Maciej Ugorski; Piotr Dziegiel; Jaroslaw Suchanski
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

5.  The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.

Authors:  Francesca Spinella; Valentina Caprara; Roberta Cianfrocca; Laura Rosanò; Valeriana Di Castro; Emirena Garrafa; Pier Giorgio Natali; Anna Bagnato
Journal:  Carcinogenesis       Date:  2014-01-28       Impact factor: 4.944

6.  Molecular regulation of lymphangiogenesis in development and tumor microenvironment.

Authors:  Taotao Li; Jianfeng Yang; Quansheng Zhou; Yulong He
Journal:  Cancer Microenviron       Date:  2012-08-04

7.  Phenotypic transformation of intimal and adventitial lymphatics in atherosclerosis: a regulatory role for soluble VEGF receptor 2.

Authors:  Mahdi Taher; Shintaro Nakao; Souska Zandi; Mark I Melhorn; K C Hayes; Ali Hafezi-Moghadam
Journal:  FASEB J       Date:  2016-03-22       Impact factor: 5.191

Review 8.  Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.

Authors:  Julia Riedl; Cihan Ay
Journal:  Semin Thromb Hemost       Date:  2019-04-30       Impact factor: 4.180

9.  CLEC-2 and Syk in the megakaryocytic/platelet lineage are essential for development.

Authors:  Brenda A Finney; Edina Schweighoffer; Leyre Navarro-Núñez; Cecile Bénézech; Francesca Barone; Craig E Hughes; Stacey A Langan; Kate L Lowe; Alice Y Pollitt; Diego Mourao-Sa; Steve Sheardown; Gerard B Nash; Nicholas Smithers; Caetano Reis e Sousa; Victor L J Tybulewicz; Steve P Watson
Journal:  Blood       Date:  2011-12-20       Impact factor: 22.113

10.  CLEC-2 is required for development and maintenance of lymph nodes.

Authors:  Cécile Bénézech; Saba Nayar; Brenda A Finney; David R Withers; Kate Lowe; Guillaume E Desanti; Clare L Marriott; Steve P Watson; Jorge H Caamaño; Christopher D Buckley; Francesca Barone
Journal:  Blood       Date:  2014-02-14       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.